Navigation Links
Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
Date:8/19/2007

ommercialize products using Emisphere's drug delivery technology, or Emisphere's ability to fund such efforts with or without partners. Emisphere undertakes no obligation to update any of these statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as to the date hereof. Accordingly any forward-looking statements should be read in conjunction with the additional risks and uncertainties detailed in Emisphere's filings with the Securities and Exchange Commission, including those factors discussed under the caption "Risk Factors" in Emisphere's Annual Report on Form 10-K (file no. 000-17758) filed on March 6, 2007, and our Quarterly Report on Form 10-Q for the quarter ended March 31, 2007, filed on May 7, 2007 (file no. 000-17758).

EMISPHERE TECHNOLOGIES, INC.

Condensed Statements of Operations (Unaudited)

For the three and six months ended June 30, 2007 and 2006

(in thousands, except share and per share data)

For the three months For the six months

ended ended

June 30, June 30,

2007 2006 2007 2006

Revenue $398 $5,220 $3,207 $6,916

Costs and expenses:

Research and development 6,032 4,858 11,484 9,375

General and administrative

expenses 3,638 2,812 7,784 5,614

Depreciation and

amortization 270 972 583 1,962

Total costs and expenses 9,940 8,642 19,851 16,951

Operating loss (9,542) (3,422) (16,644) (10,035)

Other (expense) and income:

Beneficial conversion of


'/>"/>

SOURCE Emisphere Technologies, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Emisphere Technologies, Inc. Reports Clinical Data on Oral Delivery of GLP-1 and PYY
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Sygnis Pharma AG announces date for presentation of clinical results
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... , Sept. 16, 2014 Chindex International, ... ) announced that, at a special meeting of stockholders ... merger agreement (the "Merger  Agreement") by and among the ... Acquisition, Inc. ("Merger Sub"). Parent is an affiliate of ... Ms. Roberta Lipson , the CEO of the ...
(Date:9/16/2014)... Research and Markets has announced the addition of the ... offering. Animal vaccines are biological preparations used ... prepared from weakened or dead microbes that can cause a ... animal vaccines are also formulated using a part of a ... These components act as stimulating agents that trigger ...
(Date:9/16/2014)... 16, 2014 QPID Health , a leader ... headquarters in Boston and their first ... be at 175 Franklin Street in Boston ... QPID Health,s new Southern California office ... expansion will help meet the demands of customers nationwide.  Both ...
Breaking Medicine Technology:Chindex Stockholders Approve Merger 2Chindex Stockholders Approve Merger 3Global Animal Vaccines Market 2014-2018: Key Vendors are Bayer, Elanco, Merck, Novartis, Sanofi and Zoetis 2Global Animal Vaccines Market 2014-2018: Key Vendors are Bayer, Elanco, Merck, Novartis, Sanofi and Zoetis 3QPID Health Announces Major Office Expansion in Boston and Opens Facility in San Diego 2
... Switzerland, June 23 Debiopharm Group,(Debiopharm), a Swiss-based global ... of prescription drugs that target unmet medical,needs, announced that ... was launched in Germany in May 2009, by Dr ... on a preliminary basis in,Belgium. The effective commercial launch ...
... --Whole-Genome Searches Are Revealing Secrets of a Childhood Cancer-- , ... The Children,s Hospital of Philadelphia advance the search for genetic ... childhood cancer. , , Originating in the peripheral nervous ... childhood and causes 15 percent of all childhood cancer deaths. ...
Cached Medicine Technology:Salvacyl(R), Developed by Debiopharm, is Launched in two European Countries 2Gene Findings Unlocking Reasons for Neuroblastoma Risk 2Gene Findings Unlocking Reasons for Neuroblastoma Risk 3Gene Findings Unlocking Reasons for Neuroblastoma Risk 4
(Date:9/16/2014)... September 16, 2014 Cliff Lake Dental Care ... Kristaleen is the newest dental hygienist to join Dr. Rauchwarter's ... to working with her and knows she will bring many ... , Kristaleen grew up in River Falls, WI. She ... College in 2003 and practiced dental assisting in the Twin ...
(Date:9/16/2014)... in helping people to reach their fitness and ... wearers improve their wellness by constantly monitoring their ... into companion computer programs and mobile apps. ... for these devices, researchers at the University of ... these activity monitors, such as those made by ...
(Date:9/16/2014)... CO (PRWEB) September 16, 2014 Aspen ... that it has been recognized for its high morale ... Consulting magazine “The Best Small Firms to Work For ... survey annually, with more than 10,000 consultants participating across ... Extensive employee satisfaction surveys were conducted, and firms were ...
(Date:9/16/2014)... September 14, 2014 A new study found ... (SB) stenting of true coronary bifurcation lesions yields ... The DKCRUSH-VI clinical trial is the first study ... Findings were reported today at the 26th annual ... the Cardiovascular Research Foundation (CRF), TCT is the ...
(Date:9/16/2014)... with endocrine therapy and radiation therapy as part ... care for women with hormone-receptor positive (HR+) invasive ... Fox Chase Cancer Center, however, shows that combination ... with the disease. , The results, which ... for Radiation Oncology,s 56th Annual Meeting on Sunday, ...
Breaking Medicine News(10 mins):Health News:Cliff Lake Dental Care Announces Newest Team Member 2Health News:Do wearable lifestyle activity monitors really work? 2Health News:Do wearable lifestyle activity monitors really work? 3Health News:Aspen Advisors Earns Recognition in Consulting Magazine’s "Best Small Firms to Work For" 2Health News:Aspen Advisors Earns Recognition in Consulting Magazine’s "Best Small Firms to Work For" 3Health News:Results of DKCRUSH-VI trial reported at TCT 2014 2Health News:Benefit of endocrine therapy in elderly women with low risk hormone receptor positive breast cancer? 2Health News:Benefit of endocrine therapy in elderly women with low risk hormone receptor positive breast cancer? 3
... patients covered by compensation have worse physical and life-quality ... to new research. ,Orthopaedic injury, usually ... form of hospitalisation in Australia, according to the study ... ,,The authors Professor Peter Cameron, Head of ...
... health doctors argue for routine opt-out HIV testing in ... departments and hospital wards. ,In the first article, ... people in the UK with HIV do not know they ... for pregnant women and people attending genitourinary (GUM) clinics. ...
... taken before meals, can improve blood glucose control for people ... with short-acting injected insulin that is taken in addition ... according to a new review of the body of published ... 2 diabetes typically have to take extra insulin at mealtimes ...
... AVGO), a late stage biotechnology company that develops central ... selection of the optimal dose of HD-02, its ... ,This dose was determined in an open-label ... Dr. Diana Rosas of Massachusetts General Hospital (MGH), and ...
... mass displacement of people in sub-Saharan Africa do not necessarily ... refugee agency said on Friday. ,Contradicting a ... the UN High Commissioner for Refugees (UNHCR) said that out ... actually had a lower rate than surrounding host communities. ...
... who was detained for 30 years in his native Cuba, realized ... a ceremony in Miami. ,Now, he says, his ... the former fisherman is convinced he will outlive the ailing Cuban ... far less healthy than I am, he can hardly talk," Temprana ...
Cached Medicine News:Health News:Doctors Call for Opt-out Approach to HIV Testing 2Health News:Inhaled Insulin for Type 2 Diabetes Shows Mixed Results 2Health News:Inhaled Insulin for Type 2 Diabetes Shows Mixed Results 3Health News:Avicena to Advance Huntington's Disease Clinical Program into Phase III 2Health News:No Clear Link Between Conflict, Rape and HIV: UN Study 2Health News:The American Dream Comes True for 105-year-old Cuban 2
... intended for the immunochromatographic, qualitative determination ... Strip Gonorrhea is based on the ... determination of gonorrhea antigen in the ... system as an aid in the ...
The IntraStent DoubleStrut Biliary Stent represents a completely new direction in stent design. The combination of parallel struts and unique cell geometry provide unparalleled performance....
The Smart Check Syphilis Device is a qualitative membrane device based immunoassay for the detection of TP (Treponema Pallidum) antibodies in whole blood/serum/plasma. For professional in vitro diagn...
Bio-Quant, Inc. OneStep hCG InstaTest is an immunochromatographic assay designed for qualitative determination of human chorionic gonadotropin (hCG) in urine for early detection of pregnancy....
Medicine Products: